Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual
The eighth-edition melanoma staging system, derived from over 46,000 patients, refined thickness cut-offs and node categories and created the stage IIIA to IIID subgroups whose very different outlooks now guide adjuvant therapy decisions.
Overview
Description of the American Joint Committee on Cancer eighth-edition staging for melanoma, based on an international database of 46,000 patients, including changes to T1 subcategories, removal of mitotic rate from T1 staging, revised N categories incorporating microsatellites and in-transit disease, new stage III subgroups, and M1 subcategories with lactate dehydrogenase.
- Five-year melanoma-specific survival ranges from 93 percent in stage IIIA to 32 percent in stage IIID.
- Stage IIB and IIC have worse survival than stage IIIA.
Stage IIB, IIC and III on this site's melanoma pages, and the recognition that stage IIIA has a better prognosis than stage IIB or IIC, come from this system.
- Survival estimates predate modern adjuvant therapy.
Similar pages
not linked directly; found by shared links- TermUlceration (melanoma)
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).
- TermBreslow thickness
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).
- TermWide local excision
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).
- TrialINTerpath-001 (V940-001)
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).
- TreatmentIntismeran autogene
Shares Stage IIB and IIC melanoma, Stage III melanoma (after surgery).